Shield Therapeutics (LON:STX) Rating Reiterated by Peel Hunt

Peel Hunt reissued their buy rating on shares of Shield Therapeutics (LON:STX) in a research report sent to investors on Monday, June 3rd, ThisIsMoney.Co.Uk reports.

Other equities research analysts also recently issued reports about the company. Liberum Capital increased their price target on Shield Therapeutics from GBX 80 ($1.05) to GBX 116 ($1.52) and gave the stock a buy rating in a research report on Tuesday, February 19th. FinnCap assumed coverage on Shield Therapeutics in a research report on Tuesday, May 14th. They set a corporate rating and a GBX 200 ($2.61) price target on the stock.

Shares of LON STX traded down GBX 3.50 ($0.05) during mid-day trading on Monday, hitting GBX 110.50 ($1.44). The stock had a trading volume of 70,883 shares, compared to its average volume of 48,665. The stock’s 50 day moving average price is GBX 109.98. Shield Therapeutics has a twelve month low of GBX 27 ($0.35) and a twelve month high of GBX 122.25 ($1.60). The stock has a market cap of $131.14 million and a price-to-earnings ratio of -73.67.

In other news, insider James M. Karis bought 4,000 shares of the stock in a transaction dated Tuesday, April 16th. The shares were acquired at an average cost of GBX 81 ($1.06) per share, with a total value of £3,240 ($4,233.63). Also, insider Mark Sampson bought 22,042 shares of the stock in a transaction dated Thursday, April 25th. The shares were purchased at an average cost of GBX 91 ($1.19) per share, for a total transaction of £20,058.22 ($26,209.62).

About Shield Therapeutics

Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Recommended Story: What is the Book Value of a Share?

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply